菲立莫妥在腹部和盆腔的药代动力学:1.5 T和3.0 T MRI弛豫测量给药研究
研究在12名健康志愿者中于1.5 T和3.0 T MRI上用R2*弛豫测量评估菲立莫妥(FE)在腹部和盆腔的药代动力学,志愿者随机接受2 mg/kg或4 mg/kg剂量。单核吞噬细胞系统(MPS)器官R2*峰值在FE2mg组为第1天、FE4mg组为第1至4天,除脾(1.5 T时)和肝外MPS R2*至第30天仍升高;淋巴结药代动力学与MPS器官不同,与非MPS解剖和血池平行。
要点
- MPS器官(肝、脾、骨髓)R2*峰值:FE2mg组第1天,FE4mg组第1至4天。
- 除脾(1.5 T时)和肝外,两剂量MPS R2*至第30天仍高于基线。
- 淋巴结R2*变化与非MPS解剖相似,任何时间点无差异。
核心结论
- 菲立莫妥在淋巴结的药代动力学与MPS器官不同,与非MPS解剖和血池平行。
研究设计与样本
- 研究为给药研究,纳入12名健康志愿者(6名女性;平均年龄44.3岁±12.2[标准差])。
- 志愿者随机接受菲立莫妥2 mg/kg(FE2mg,n=5)或4 mg/kg(FE4mg,n=6)。
- 于2015年4月至2016年1月间在1.5 T和3.0 T MRI上行R2*弛豫测量,每位志愿者在第1、2、4、7和30天共5个时间点重复扫描。
- 由一名有MRI弛豫测量经验的放射科医师测量MPS器官(肝、脾、骨髓)、非MPS解剖(肾、胰腺、肌肉)、腹股沟淋巴结和血池的R2*。
关键影像表现/征象
- MPS器官R2*峰值时间:FE2mg组为第1天,FE4mg组为第1至4天(P < .001至P < .002)。
- 非MPS解剖、淋巴结和血池R2*峰值时间:两剂量组均为第1天(P < .001至P < .09)。
- 除脾(1.5 T时)和肝外,两剂量组MPS R2*至第30天仍升高(P = .02至P = .03)。
- 除肾和胰腺外,非MPS、淋巴结和血池R2*恢复至基线:FE2mg组第2至4天(P = .06至P = .49),FE4mg组第4至7天(P = .06至P = .63)。
- 非MPS与淋巴结R2*变化在任何时间点均无差异(范围,1-71 sec-1 vs 0-50 sec-1;P = .06至P = .97)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The off-label use of ferumoxytol (FE), an intravenous iron preparation for iron deficiency anemia, as a contrast agent for MRI is increasing; therefore, it is critical to understand its pharmacokinetics. Purpose To evaluate the pharmacokinetics of FE in the abdomen and pelvis, as assessed with quantitative 1.5- and 3.0-T MRI relaxometry. Materials and Methods R2*, an MRI technique used to estimate tissue iron content in the abdomen and pelvis, was performed at 1.5 and 3.0 T in 12 healthy volunteers between April 2015 and January 2016. Volunteers were randomly assigned to receive an FE dose of 2 mg per kilogram of body weight (FE2mg) or 4 mg/kg (FE4mg). MRI was repeated at 1.5 and 3.0 T for each volunteer at five time points: days 1, 2, 4, 7, and 30. A radiologist experienced in MRI relaxometry measured R2* in organs of the mononuclear phagocyte system (MPS) (ie, liver, spleen, and bone marrow), non-MPS anatomy (kidney, pancreas, and muscle), inguinal lymph nodes (LNs), and blood pool. A paired Student t test was used to compare changes in tissue R2*. Results Volunteers (six female; mean age, 44.3 years ± 12.2 [standard deviation]) received either FE2 mg (n = 5) or FE4 mg (n = 6). Overall R2* trend analysis was temporally significant (P < .001). Time to peak R2* in the MPS occurred on day 1 for FE2mg and between days 1 and 4 for FE4mg (P < .001 to P < .002). Time to peak R2* in non-MPS anatomy, LNs, and blood pool occurred on day 1 for both doses (P < .001 to P < .09). Except for the spleen (at 1.5 T) and liver, MPS R2* remained elevated through day 30 for both doses (P = .02 to P = .03). Except for the kidney and pancreas, non-MPS, LN, and blood pool R2* returned to baseline levels between days 2 and 4 at FE2mg (P = .06 to P = .49) and between days 4 and 7 at FE4mg (P = .06 to P = .63). There was no difference in R2* change between non-MPS and LN R2* at any time (range, 1-71 sec-1 vs 0-50 sec-1; P = .06 to P = .97). Conclusion The pharmacokinetics of ferumoxytol in lymph nodes are distinct from those in mononuclear phagocyte system (MPS) organs, parallel non-MPS anatomy, and the blood pool. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Wells SA, Schubert T, Motosugi U, et al. Pharmacokinetics of Ferumoxytol in the Abdomen and Pelvis: A Dosing Study with 1.5- and 3.0-T MRI Relaxometry. Radiology. 2019. PMID: 31714191. doi:10.1148/radiol.2019190489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。